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Abstract
Background: Interleukin-7 receptor alpha (IL-7Rα) represents a biomarker with potential applications in rheumatoid
arthritis (RA) diagnosis and therapy. We have therefore searched by phage display potential IL-7Rα specific peptides
with the primary goal being to develop in vivo molecular imaging tools.
Methods: IL-7Rα-targeted peptides were searched within a disulfide-constrained combinatorial phage displayed
library of random linear heptapeptides. The apparent dissociation constant (Kd) and half maximal inhibition constant
(IC50) were estimated for phage clones and synthesized peptides by ELISA. We used 5-Aza-2’-deoxycytidine (ADC)-
stimulated Jurkat cells and human synovial tissue from patients with RA for in vitro characterization of peptides. For
molecular imaging studies performed by magnetic resonance imaging (MRI), experimental arthritis was induced in
DBA/1 male mice by immunization with an emulsion of complete Freund’s adjuvant and type II collagen from
chicken sternal cartilage.
Results: After several steps of phage display and peptide screening, two IL-7Rα-specific heptapeptides (P258 and
P725) were selected from the initial library, based on their affinity for the target (extracellular domain of IL-7Rα,
which contains a fibronectin type III repeat-like sequence). P258 (a linear peptide obtained by removing the
Cys-constraint) had the lowest affinity for fibronectin itself and was therefore proposed for molecular imaging.
After grafting to ultra-small superparamagnetic particles of iron oxide (USPIO), P258 produced a strong negative
contrast on MRI in mice with collagen-induced arthritis (CIA), even at 2 hours post injection. The co-localization of
USPIO-P258 with IL-7Rα-expressing cells in the synovial tissue from CIA mice and its ability to discriminate the level of
IL-7R expression and the disease severity confirmed its efficacy as an in vivo IL-7Rα imaging agent. Interestingly, the
cyclic peptide (P725), which was less adequate for molecular imaging because of higher affinity for fibronectin,
had a strong ability to compete with IL-7 for the IL-7Rα binding sites, making it a potential candidate for blocking
applications. Accordingly, P725 prevented the signal transducer and activator of transcription 5 (STAT5) activation
induced by IL-7 in ADC-stimulated Jurkat cells.
Conclusions: The two peptides identified in this work demonstrate that IL-7Rα targeting in RA presents potential
applications for in vivo molecular imaging and putative blocking purposes.
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Background
Rheumatoid arthritis (RA) is a chronic and debilitating
autoimmune disease that causes joint damage, de-
creased quality of life and cardiovascular complications,
among other comorbidities. With 5–50 per 100,000
new cases annually, RA occurs in 0.5–1 % of adults in
industrialized countries, being more frequent in women
and elderly people [1].
Interleukin-7 (IL-7) is an anti-apoptotic cytokine,
essential for T cell proliferation, development and
homeostasis. It is also involved in B cell development.
The IL-7 receptor (IL-7R) comprises two heterodimeric
subunits, IL-7Rα and the common γ-chain (γc) respect-
ively. IL-7Rα is composed of a 195 amino acid intracel-
lular domain, a 25 amino acid transmembrane domain
and an extracellular region comprising 219 amino acids.
Four invariant cysteine residues located at the N-terminus
of the extracellular domain are involved in intrachain
disulfide bond formation. A Trp-Ser-X-Trp-Ser (WSXWS)
motif is located close to the transmembrane domain of
the extracellular region of IL-7Rα, which also contains a
fibronectin (FN) type III-like domain. The intracellular
domain of IL-7Rα is responsible of signal transduction via
the recruitment of signal transducing molecules, such
as the Janus kinase 1 (Jak1), the signal transducer and
activator of transcription 5 (STAT5) and the src family
of tyrosine kinases, and is involved in the IL-7-
dependent activation of phosphatidylinositol 3-kinase
(PI3K) [2, 3]. IL-7 binding to its receptor triggers sev-
eral signaling cascades, i.e., Jak/STAT, PI3K, Ras and
mitogen-activated protein kinase (MAPK)/extracellular
signal-related kinase (ERK), being essential for lympho-
cyte survival, homeostasis and differentiation [2–4].
IL-7 and IL-7R are over-expressed in the RA synovium.
IL-7 plays a crucial role in T cell activation and osteoclas-
togenesis by upregulating T cell-derived cytokines, includ-
ing the receptor activator of nuclear factor-κB ligand
(RANKL) [5]. In RA synovitis, not only T cells, but
also synovial macrophages and fibroblasts over-express
IL-7Rα, thereby making IL-7Rα the transcript most
differentially expressed between RA and other inflam-
matory joint conditions such as osteoarthritis, systemic
lupus erythematosus, psoriatic arthritis and gout [6–8].
Synovial fibroblasts also produce a high quantity of
soluble IL-7Rα subsequent to their stimulation by cy-
tokines such as tumor necrosis factor-α (TNFα), IL-1
and IL-17 [9–11]. According to several observations,
soluble IL-7Rα stabilizes IL-7 and amplifies its T cell
stimulatory effects [12]. The increased expression and
high serum concentrations of soluble IL-7Rα is associ-
ated with poor response to anti-TNFα therapy in
patients with RA [13, 14]. The pathogenic role of the
IL-7/IL-7R axis in RA is further illustrated in a mouse
model of the disease (collagen-induced arthritis, CIA),
in which both IL-7 or IL-7R blockade using monoclo-
nal antibodies results in significant improvements in
disease activity [15–17]. Of note, recent observations
also highlight the potential involvement of IL-7/IL-7R
in other autoimmune disorders, such as systemic lupus
erythematosus and Sjögren’s syndrome [18, 19].
As it is currently an incurable disease, diagnosis and
treatment of RA before its progression towards a debili-
tating stage is imperative for patients. Magnetic reson-
ance imaging (MRI) is reported to be the best clinical
imaging technique for the diagnosis of RA, allowing ob-
servation of the characteristic inflammation and lesions
that are not adequately displayed using conventional
radiography. Molecular imaging of specific pathological
processes in synovitis would increase the likelihood of
early diagnosis, disease staging and monitoring. Any of
the molecular actors involved in chronic inflammation,
cell proliferation and apoptosis represents putative tar-
gets for functionalized imaging probes, thus optimizing
the diagnostic capability of clinical imaging techniques
[20–23].
Our work is integrated within this clinical and scien-
tific context, by trying to develop molecular tools to
image IL-7Rα in vivo as a diagnostic biomarker, and as a
marker of response to RA therapy. To achieve this goal,
a randomized cyclic heptapeptide phage display library
was screened against IL-7Rα, leading to the identifica-
tion of two peptides specific to this biomarker, one of
them being a putative blocking agent for IL-7 (called
P725). The peptides were characterized in terms of affin-
ity, biologic activity and diagnostic potential by MRI.
The peptide dedicated to MRI applications (called P258)
was coupled to ultra-small superparamagnetic particles
of iron oxide (USPIO, an MRI contrast agent producing
a negative contrast) and its pharmacokinetics, biodistri-
bution and diagnostic potential were evaluated in mice.
USPIO present a particular interest for molecular im-
aging due to their excellent MRI efficacy, biocompati-
bility and biodegradability. The blood half-life of this
material is significantly prolonged by coating it with
hydrophilic polymers, such as poly(ethylene glycol)
(PEG), which reduce its opsonization and the clearance
by the reticuloendothelial system, thus improving the
targeting of specific biomarkers [24, 25]. The vectoriz-
ing peptide P258 and PEG used as a coating material
were covalently coupled to the carboxyl groups exposed
at the surface of USPIO.
Methods
The experiment of phage display and characterization of
the candidate phage clones
Phage display library and Escherichia coli host strain
IL-7Rα-targeted peptides were searched within a
disulfide-constrained combinatorial library of random
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linear heptapeptides fused to the minor coat protein
(pIII) of M13 bacteriophage (Ph.D.-C7C™ phage display
library, New England BioLabs® Inc., Westburg b.v.,
Leusden, The Netherlands). The E.coli host ER2738 (E.
coli K12 ER2738, F+, tetracycline-resistant strain; New
England BioLabs®) was used for phage amplification
and clone isolation.
The panning of phage display library against IL-7Rα
The phage display library was panned against recombinant
human IL-7 Rα/Fc chimera (R&D Systems, Abingdon,
UK), which was immobilized alternatively on Dynabeads®
Protein A or G (Invitrogen Dynal, Merelbeke, Belgium)
during the four rounds of biopanning. To increase the
peptide specificity and stringency, the target concentration
was diminished from 100 nM to 75 nM during the pan-
ning rounds; Dynabeads Protein A/Protein G were alter-
nated at each round of panning; the incubation time with
the target was reduced stepwise; the incubation times
with blocking or related proteins (BSA, Fc-IgG (human
IgG, Fc fragment from plasma, Calbiochem, VWR,
Leuven, Belgium), fragment 3 of recombinant human
FN-1 (R&D Systems)) were increased stepwise, and the
Tween-20 concentration was increased at each panning
round (i.e., 0.1–0.5 %) in the incubation and rinsing
buffer (phosphate-buffered saline, PBS; per liter: 8 g
NaCl, 0.2 g KCl, 2.31 g Na2HPO4 × 12 H2O, 0.2 g
KH2PO4, pH 7.4). The detailed bio-panning protocol is
available in Additional file 1: Methods.
Evaluation of the affinity of the phage clones for IL-7Rα
For affinity tests, IL-7Rα was diluted at a concentration
of 10 μg/mL in 0.1 M NaHCO3, pH 8.6, and immobi-
lized overnight at 4 °C. The control wells were coated
with 5 mg/mL of BSA or with 10 μg/mL of FN and used
to evaluate the phage non-specific binding. Phages were
diluted in PBS supplemented with 0.5 % Tween-20
(PBST), and were incubated with both test and control
wells (2 h, 37 °C). Bound phages were detected with
horseradish peroxidase (HRP)-conjugated anti-M13 anti-
body (Amersham Pharmacia Biotech Benelux, Roosendaal,
The Netherlands) diluted 1:5000 in THBS completed
with 5 mg BSA/mL. The staining reaction was devel-
oped with 2,2´-Azino-bis(3-Ethylbenzothiazoline-6-
sulfonic acid) (ABTS), diamonium salt (Sigma-Aldrich,
Bornem, Belgium) solution completed with 0.05 %
H2O2. The optical density (OD)405 was measured using a
microplate reader (StatFax-2100, Awareness Technology,
Fisher Bioblock Scientific, Tournai, Belgium).
To confirm the binding specificity of three selected
clones, immobilized IL-7Rα was pre-incubated with a
range of human recombinant IL-7 (R&D Systems) con-
centrations. The phages were added 30 minutes later at
a concentration equal to their apparent dissociation
constant (K*d) and the incubation was continued for one
more hour. Phages bound to the target were detected
with HRP-conjugated anti-M13 antibody as described
above. The affinity tests are additionally described in
Additional file 1: Methods.
Sequencing of the phage clones
Phage DNA was isolated and purified by phenol extrac-
tion–ethanol precipitation. The sequence reaction
(Mastercycler Personal) was carried out by the Sanger
method, using the Quick Start Kit (Beckman CoulterTM,
Analis, Namur, Belgium) and a 20-base primer (5’-CC
CTCATAGTTAGCGTAACG-3’) (New England Biolabs).
Sequence reading was performed with JaMBW 1.1 soft-
ware (http://bioinformatics.org/JaMBW/), and peptide
sequences were aligned with the basic local alignment
search tool (BLAST).
Characterization of the selected IL-7Rα-binding peptides
Three peptides were selected for synthesis and subse-
quent evaluation. They were synthesized as biotinyl-
ated or not biotinylated 8-amino-3,6-dioxaoctanoyl
derivatives and encoded as follows: P722 (clone 36/R2:
C-PHPQRPA-C), P725 (clone C29/R3: C-KIMKSMP-C)
and P726 (clone C37/R2: C-ASACPPH-C). Peptide 726
was also synthetized in a linear version (ASACPPH) and
was encoded as P258.
Estimation of the apparent dissociation constant (K*d)
Serial dilutions of biotinylated peptides were incubated
with IL-7Rα or FN immobilized on ELISA plates as
described above and blocked with protein-free blocking
buffer (PFBB) (Perbioscience, Erembodegem, Belgium).
Peptides bound to the target were detected with a goat
anti-biotin antibody, followed by a peroxidase-conjugated
anti-goat antibody made in horse (both from Vector
Labconsult, Brussels, Belgium). The staining reaction was
developed with ABTS/H2O2, and OD405 was measured
with a microplate reader. The protocol is largely described
in Additional file 1: Methods.
Estimation of the half maximal inhibitory concentration (IC50)
The K*d of IL-7 was determined by incubating a range
of IL-7 concentrations with immobilized IL-7Rα. The
bound IL-7 was then detected with a polyclonal goat
anti-human IL-7 antibody (R&D Systems) followed by a
horse anti-goat antibody coupled to HRP (Vector Lab-
consult). To estimate the IC50 of peptides, they were
pre-incubated with IL-7Rα-coated wells in a range of
concentrations; IL-7 was then added at a concentration
equal to its K*d and the incubation continued for an-
other 90 minutes. IL-7 bound to the target was de-
tected as described. The detailed protocol is available in
Additional file 1: Methods.
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Binding of peptides to Jurkat cells and co-localization with
IL-7Rα by immunofluorescence
Jurkat cells were cultured in RPMI-1640 culture
medium supplemented with 10 % newborn calf serum
heat-inactivated and 1 % antibiotic-antimycotic (all
from Invitrogen). The cells were stimulated with
0.4 μM of 5-Aza-2’-deoxycytidine (ADC, Sigma-Aldrich)
[26]. The stimulated cells were immobilized on poly-L-
lysine (Sigma-Aldrich) coated coverslips and fixed in a solu-
tion of 4 % formaldehyde (Sigma-Aldrich). After blocking
the cells with PFBB, they were co-incubated with mouse
anti-human IL-7Rα monoclonal antibody (Sigma-Aldrich)
and biotinylated peptides P258 (0.04 μM) or P725 (5 μM).
Biotinylated peptides were detected with a goat anti-biotin
antibody followed by fluorescein-conjugated rabbit anti-
goat antibody (both from Vector Labconsult). Anti-IL-7Rα
antibody was detected with Texas Red horse anti-mouse
antibody (Vector Labconsult). Control samples consisted of
ADC-stimulated or non-stimulated (NS) Jurkat cells incu-
bated with low-affinity peptide binders (e.g., P255, P259), a
mouse IgG isotype control, or with secondary antibodies
after excluding the primary antibodies. The coverslips were
mounted on slides with Vectashield mounting medium for
fluorescence with 4',6-diamidino-2-phenylindole (DAPI)
(Vector Labconsult) and observed on a DM2000 Leica
microscope equipped with a DFC 425C camera (Leica
Microsystems, Groot Bijgaarden, Belgium). The protocol is
additionally described in Additional file 1: Methods.
Immunohistochemical detection of biotinylated P258 and
of IL-7Rα in knee biopsy samples from patients with RA
Synovial knee biopsies were obtained by needle arthros-
copy in three untreated patients with active RA. Fresh
biopsy samples (between four and six per patient) were
fixed overnight in 10 % formalin buffer at pH 7.0 and
embedded in paraffin. Sections of 5 μm thickness were
cut and treated to remove paraffin (two baths of toluene
for 10 minutes each) and rehydrate them (three baths of
95 % ethanol for 10 minutes each, followed by 10 mi-
nutes in running cold tap water and 5 minutes in dis-
tilled water), followed by unmasking of epitopes in a
citrate solution according to standard procedures. The
endogenous peroxidases were blocked with 0.3 % H2O2
in PBS and the non-specific epitopes were blocked with
PFBB.
The tissue sections were incubated with mouse anti-
human IL-7Rα monoclonal antibody (Sigma-Aldrich),
followed by a peroxidase-conjugated monoclonal anti-
mouse antibody produced in goat (Sigma-Aldrich). The
sections were then stained with 0.05 % 3,3'-diamino-
benzidine (DAB) completed with 0.02 % H2O2 in PBS.
Finally, they were counterstained with Hemalun and
Luxol fast blue and mounted in a permanent medium.
Endogenous biotin was blocked with a blocking kit
(Invitrogen) before incubating the histologic sections with
1 μM of P258 (or with control peptides P255 and P259),
followed by a goat anti-biotin antibody and a peroxidase-
conjugated anti-goat antibody made in horse (both from
Vector Labconsult). The staining and counterstaining
were performed as described for anti-IL-7Rα monoclonal
antibody. Additional information is available in Additional
file 1: Methods. The study was approved by the Ethical
Committee of the Université Catholique de Louvain, and
informed consent was obtained from all patients.
Phospho-STAT5 detection on Jurkat cells and modulation
by peptide P725
The experiment was performed in triplicate on ADC
stimulated and NS cells distributed in several culture
tubes treated with different compounds diluted in the
culture medium as follows: (A) cells treated for 48 h
with IL-7 (eBioscience, Vienne, Austria); (B) cells pre-
incubated for 30 min with P725; (C) cells pre-incubated
for 30 min with mouse anti-human IL-7Rα monoclonal
antibody (Sigma-Aldrich). IL-7 was then added in sam-
ples B and C, and incubation continued for 48 h. The
solutions were replaced every day after culture tube cen-
trifugation and supernatant removal.
The treated cells were rinsed and immobilized on
poly-L-lysine-coated coverslips. They were fixed with
4 % formaldehyde and 100 % methanol, and then
blocked with a solution of 5 % normal goat serum and
0.3 % Triton X-100 prepared in PBS. Subsequently, the
cells were co-incubated with human Phospho-STAT5
(Tyr694 D47E7 XP®) antibody made in rabbit and anti-
Pan-keratin (C11) antibody made in mouse (both from
Bioké, Leiden, The Netherlands). The cells were subse-
quently co-incubated with fluorescein-conjugated goat
anti-rabbit antibody and horse Texas Red-conjugated
anti-mouse antibody (both from Vector Labconsult).
The coverslips were finally mounted on slides with Vec-
tashield mounting medium for fluorescence with DAPI
(Vector Labconsult). Detailed protocols are available in
Additional file 1: Methods.
The signal intensity (SI) was measured on microphoto-
graphs corresponding to three to six different micro-
scopic fields using the ImageJ software (National
Institutes of Health, USA), and the relative ratio of fluor-










Evaluation of the lysosome content of Jurkat cells
For lysosome tracking, Jurkat cells stimulated and
treated as described above were incubated with a
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solution of Hoechst 33342 (for nuclei staining),
followed by Lysotracker® Red DND-99 (Image-mITT
LIVE lysosomal and nuclear labeling kit, Life tech-
nologies, Merelbeke, Belgium). The cells were then
mounted between microscope slides and coverslips,
observed under a microscope and the RRFL was evalu-
ated as described above . The protocol is additionally
described in Additional file 1: Methods.
Preparation and characterization of the imaging probe
Synthesis and characterization of USPIO-P258
Peptide P258 was synthesized by the company PolyPeptide
(Strasbourg, France) as an 8-amino-3,6-dioxaoctanoyl
(two PEG units, used as linker) derivative (PolyPeptide,
Strasbourg, France), the C-terminus of the peptide being
amidated. It was then covalently conjugated to USPIO as
previously described [24]. The vectorized nanoparticles
(USPIO-P258) were rendered stealth by a PEG coat, which
was also used to prepare the non-specific nanoparticles
(USPIO-PEG). The transverse relaxivity, r2, evaluated at
37 °C and 60 MHz in mouse blood plasma was of 98.94 s
−1mM−1 for USPIO-P258 and of 107.75 s−1mM−1 for
USPIO-PEG. The hydrodynamic diameter of USPIO-P258
was measured by photon correlation spectroscopy (PCS,
Brookhaven system BI-160 (New York, USA) equipped
with a He-Ne laser (=633 nm, 35 mW)) after 2 h of incu-
bation at room temperature in water (48 nm), PBS
(40 nm) and RPMI culture medium (37 nm).
The K*d of USPIO-P258 for the binding to IL-7Rα was
determined by ELISA, using a rabbit anti-PEG monoclo-
nal antibody (Abcam, Cambridge, UK), biotinylated goat
anti-rabbit IgG and Vectastain ABC kit (both from Vec-
tor Labconsult) as previously described [25]; the IC50 of
USPIO-P258 was evaluated using the same method as
that described previously. The eventual cytotoxic effects
of USPIO-P258 were determined on HepaRG™ cell line
(Life Technologies) using the MTT assay (in vitro toxi-
cology assay kit MTT-based, Sigma-Aldrich) as previ-
ously described [25].
Evaluation of USPIO-P258 binding to Jurkat cells
ADC-stimulated or NS Jurkat cells were incubated (n = 3/
experimental group) with USPIO-P258 or USPIO-PEG at
an iron concentration of 1–3 mM. The cells were subse-
quently rinsed and mineralized in acidic conditions, and
iron concentration in cell samples was determined by
relaxometry on a Bruker Minispec Mq60 (Karlsruhe,
Germany) based on a calibration curve. For magnetic res-
onance imaging (MRI) analysis and the measurement
of the transverse relaxation time (T2), the cells incu-
bated with contrast agents were suspended in 2 % gel-
atin prepared in PBS. The MR images were acquired
on a 300 MHz (7 T) Bruker Biospec imaging system
(Ettlingen, Germany). A T2-weighted Rapid Acquisition
with Relaxation Enhancement (RARE) sequence was used
for cell visualization. The T2 was measured with a Multi-
Slice-Multi-Echo (MSME) sequence. The results were
expressed as transverse relaxation rates (R2 = 1/T2) nor-
malized to gelatin (R2
Norm) and measured in s−1.
USPIO-P258 was co-localized with IL-7Rα expressed
by Jurkat cells using an immunofluorescence protocol.
At the end of the MRI studies, the cells were recovered
from gelatin, resuspended in PBS and immobilized on
poly-L-lysine coated coverslips, before being fixed and
blocked as described previously. The cells were then co-
incubated with mouse anti-human IL-7Rα monoclonal
antibody (Sigma-Aldrich) and with rabbit monoclonal
anti-PEG antibody (Bio-Connect/Epitomics, Huissen,
The Netherlands). The cells were subsequently co-
incubated with Texas Red horse anti-mouse antibody and
fluorescein goat anti-rabbit antibody (both from Vector
Labconsult). The coverslips were finally mounted on slides
with a mounting medium for fluorescence (Vector Lab-
consult). The RRFL was evaluated as described above. The
protocols are detailed in Additional file 1: Methods.
Evaluation of pharmacokinetic parameters,
biodistribution and diagnostic ability of USPIO-P258 by mo-
lecular imaging
The experiments performed on animals were approved by
the Ethics Committee of the University of Mons and they
comply with the Directive 2010/63/EU. For pharmacokin-
etics and biodistribution evaluation, NMRI mice (n = 3 per
time point; Harlan, Horst, The Netherlands) were injected
with USPIO-P258 at 100 μmol Fe/kg body weight (b.w.).
The pharmacokinetics and biodistribution of USPIO-PEG,
used as a control contrast agent, were previously deter-
mined [25]. The negative control animals were left
untreated. The blood, urine and organs (kidneys, liver,
spleen and lungs) were collected at various time intervals
after the injection of the contrast agent, and R2 was mea-
sured on a Bruker Minispec mq60. Several pharmacoki-
netic parameters (the elimination half-life (Te1/2), the
volume of distribution steady state (VDss) and the total
clearance (Cltot)) were calculated after measuring the
blood concentration of contrast agents [24, 25].
For molecular imaging studies, autoimmune RA was
induced in DBA/1 male mice (n = 4 per experimental
group) aged 10 weeks (Harlan), by immunization with
an emulsion of complete Freund’s adjuvant and type II
collagen from chicken sternal cartilage (Sigma-Aldrich)
as described [27]; the healthy control mice were left
untreated (n = 4 per experimental group). The mice were
distributed into four groups of four mice (two CIA and
two healthy groups) and were injected intravenously
(i.v.) in the caudal vein at a dose of 100 μmol Fe/kg b.w.
with either USPIO-P258 or USPIO-PEG for MRI studies;
the mice not injected with contrast agents were used as
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controls for relaxometric studies. The acquisition of im-
ages started immediately after contrast agent injection
with RARE or 3D fast imaging with steady-state preces-
sion (FISP) sequences.
Signal intensity (SI) values for each time point were
measured on RARE images within regions of interest
(ROIs) drawn manually at the level of the paw using the
ImageJ image analysis software (National Institutes of
Health, USA). The standard deviation (SD) of the noise
was measured in a region situated out of the animal’s
image. SI enhancement (ΔSNR%) was calculated for each
sagittal or coronal image according to the following
equation:





   100
where SNR = signal-to-noise ratio, SIpost = post-contrast
SI, and SIpre = pre-contrast SI.
Technical details are presented in Additional file 1:
Methods.
The total area (TA) occupied by black pixels in pre-
contrast and 108 minutes post-contrast (thresholded to
the pre-contrast level) RARE images of the hind limbs of
CIA mice injected with USPIO-P258 was evaluated
using the ImageJ software as previously described [24].
Then, the percentage difference of TA (%DTA) in post-
contrast as compared to the pre-contrast images was
calculated.
Biodistribution, IL-7Rα expression, Perls’-DAB staining of
USPIO derivatives on paw samples and Masson’s Trichrome
staining; immunofluorescent co-localization of USPIO-P258
with IL-7Rα
At the end of the MRI studies, the mice were killed by a
lethal dose of sodium pentobarbital (600 mg/kg b.w.,
intraperitoneal (i.p.)) and paws were harvested for (im-
muno)histochemical and biodistribution studies after
transcardial perfusion with PBS. Biodistribution in
freshly sampled paws was evaluated as described previ-
ously, by measuring the R2 on a Bruker Minispec mq60
working at 60 MHz and 37 °C. For (immuno)histochem-
ical studies, paws were fixed in buffered paraformalde-
hyde and decalcified in Biodec-R (Bio-optica Milano
s.p.a) for 8 days before paraffin embedding. IL-7Rα was
detected with mouse anti-IL-7Rα monoclonal antibody
and peroxidase-conjugated monoclonal anti-mouse anti-
body produced in goat (both from Sigma-Aldrich) as
described previously. USPIO derivatives were detected
on paw sections by histochemical analysis, using the
Perls’-DAB iron staining protocol [24, 28], while the paw
morphology was studied after Masson’s trichrome stain-
ing using the Accustain® kit (Sigma-Aldrich) as previ-
ously described [24, 25].
USPIO derivatives were also co-localized with IL-7Rα-
expressing cells by co-incubating paw sections with rat
anti-PEG (Abcam) and mouse anti-IL-7Rα (Sigma-Aldrich)
monoclonal antibodies, followed by Texas red-conjugated
goat anti-rat and Fluorescein-conjugated horse anti-mouse
antibodies (both from Vector Labconsult). The protocols
are additionally described in Additional file 1: Methods.
The TA occupied by IL-7Rα staining on the paw sec-
tions of CIA mice injected with USPIO-P258 was then
quantified on microphotographs using the ImageJ soft-
ware. The coefficient of correlation r2 was calculated
and the %DTA obtained after analyzing the MR images;
these two parameters were also correlated with the
severity score of CIA as determined on living mice ac-
cording to the definitions provided by Brand et al. [27].
Statistical analysis
The results are expressed as means ± SD. One-way ana-
lysis of variance (ANOVA), performed with SigmaPlot
11.0 software, was applied to compare different experi-
mental groups. For the groups where the equal variance
test was not satisfied, the statistical significance was fur-
thermore confirmed after applying the Holm-Sidak and
Bonferroni tests. Results were considered statistically
significant at p < 0.05.
Results
Identification and characterization of the candidate
phage clones
A disulfide constrained heptapeptide phage display li-
brary was screened against the extracellular domain of
IL-7Rα (E21–D239), which contains an FN type III
repeat-like sequence (A131–I231). To remove the poten-
tial binders to FN type III domain, the phage library was
pre-selected against FN before being screened against
IL-7Rα. After four rounds of selection, the affinity of
the phage pools towards IL-7Rα was evaluated and
compared to that for BSA, used as a blocking agent
(Additional file 2: Figure S1A and B). The results show
that the second and third rounds of panning present an
optimal binding to IL-7Rα, whereas the fourth round
had lost its affinity. We therefore isolated 102 clones is-
sued from the second and third rounds of panning, and
the K*d against IL-7Rα and FN was determined. Among
them, 12 clones (9 from the second round and 3 from
the third round) presented the highest affinity for IL-
7Rα, with K*d values that ranged from 0.21 nM to 4.15
nM (Additional file 2: Figure S1C and D). The K*d of
their binding to FN was variable and ranged between
99.5 μM and 1.98 nM. Based on their Kd
FN/Kd
IL-7Rα
ratio (477, 163 and 6 for the strongest binders), three
clones (36/R2, 29/R3 and 37/R2) were selected for supple-
mental characterization (see Additional file 2: Figure S2
for individual K*d values).
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The binding specificity was furthermore validated for
these three clones by competing them with IL-7. The
IC50 of IL-7 estimated in these conditions provides in-
formation on the amount of IL-7 required to dissociate
phages from their binding sites. In other words, the
higher IC50 value, the stronger binder is the phage clone
candidate. We have therefore identified an IC50 value of
2.41 × 10−6 M, 3.98 × 10−8 M and 5.10 × 10−6 M for the
competition between IL-7 and the three selected clones
(Table 1; Additional file 2: Figure S2).
The peptide sequence of the 12 initial candidate phage
clones was deciphered (Additional file 2: Figures S1C and
1D) and their analysis revealed a high frequency of basic
(His, Lys) and alcohol (Ser) amino acids, but also of Pro.
The alignment of the three best peptide clones with rele-
vant human proteins was searched using the basic align-
ment search tool BLAST (Table 1), and interesting
homologies were found with several serine/threonine-pro-
tein kinases, with adhesion molecules and proteins of the
extracellular matrix or involved in cytoskeletal organization,
cell migration, embryogenesis and inflammation.
Synthesis and in vitro characterization of the candidate
molecular imaging peptides
The three candidate peptides were synthesized first as
biotinylated derivatives and their K*d for IL-7Rα and
FN binding was evaluated (Fig. 1a; Additional file 2:
Figure S3); peptide expressed by clone 37/R2 was also
synthesized in a linear version by removing the Cys-
constraint. Among the four synthesized peptides, P725
(expressed by clone 29/R3; K*d of 0.11 × 10
−5 M) and
P258 (the linearized peptide expressed by clone 37/R2;
K*d of 0.06 × 10
−5 M) presented the highest affinity for
IL-7Rα, but the ratio K*d
FN/K*d
IL-7Rα revealed a specific
binding to IL-7Rα in the case of P258 (Fig. 1b). This
was even higher than that of IL-7 and their K*d
IL-7Rα was
equivalent. Taken together, these properties emphasize
P258 as the best candidate for molecular imaging of RA
after its conjugation to an imaging probe. At the same
time, the IC50 value of P725 was of 1.64 × 10
−5 M
(Additional file 2: Figure S3), highlighting it as an opti-
mal competitor of IL-7. However, its equivalent affinity
for IL-7Rα and FN renders this peptide inadequate for
molecular imaging; the ubiquitous FN expression could
generate a high potential background.
Peptides P258 and P725 (Additional file 2: Figure S4A
and B) were thus selected for further characterization
with the aim of developing in vivo imaging (P258) and
blocking (P725) applications. The theoretical biochem-
ical parameters (Table 2) show that peptide P258 has a
half-life of 4.4 h as predicted by the N-end rule [29],
while that of P725 is 1.2 h. The N-end rule stipulates
that proteasome degradation of proteins within cells
depends on the ubiquitin covalent conjugation at the N-
terminus residue of the protein to be hydrolyzed. The
primary destabilising residues are positively charged (i.e.,
lysine, arginine, histidine), whereas methionine is a stabiliz-
ing residue. The isoelectric point (pI) value and hydro-
philic properties, suggested by LogP, LogD, GRAVY and
aliphatic index, indicate that both peptides are ionized
Table 1 Alignment of peptides expressed by clones 29, 36 and 37 with relevant protein sequences (identified with Swiss-Prot acces-
sion numbers), where the homologous amino acids are shown
Peptide (IL-7 IC50) Homology
C36/R2: C-PHPQRPA-C (2.41 × 10−6 M) Suppressor of cytokine signaling 7 (O14512): 92PQPQPPA98;
Signal transducer and activator of transcription 4 (Q14765):
327HPQRP331; Fibronectin (P02751): 298PHPQPP303;
Serine/threonine-protein kinase ICK (Q9UPZ9): 591PHPGRP596
C29/R3: C-KIMKSMP-C (3.98 × 10−8 M) Fibronectin type III domain-containing protein 3B (Q53EP0):
1169MKSM1172; Serine/threonine-protein kinase ATR (Q13535):
75IMKSSP80; Serine/threonine-protein kinase mTOR (P42345):
1701MKNM—KILKNM1998; Interferon omega-1 (P05000): 171IMKSL
175; Transmembrane and immunoglobulin domain-containing
protein 1 (Q6UXZ0): 245KIMK248; Tumor necrosis factor
alpha-induced protein 8-like protein 3 (Q5GJ75): 164KIMK167;
Tyrosine-protein kinase STYK1 (Q6J9G0): 343KIMK—IMKS361;
Frizzled-9 (O00144): 429KIMK432; Cadherin-16 (O75309): 777MKGMP781
C37/R2: C-ASACPPH-C (5.10 × 10−6 M) Tumor necrosis factor receptor superfamily member 27 (Q9HAV5):
43ACPP46; Cadherin EGF LAG seven-pass G-type receptor 3 (Q9NYQ7):
1955CPPH1958; Rho GTPase-activating protein 29 (Q52LW3):
1212ASACP1216; Serine/threonine-protein kinase WNK2 (Q9Y3S1):
688APACPP—ASPCP—PP1741; Serine/threonine-protein kinase D2 (Q9BZL6):
860ACPPQ864; Phosphoserine phosphatase (P78330): 186ACPP189;
Laminin subunit alpha-1 (P25391): 276ASSCP—CPPH1019; Ephrin type-A
receptor 3 (P29320): 290CPPH293; Ephrin type-A receptor 4 (P54764):
293CPPH296; Ephrin type-A receptor 5 (P54756): 322CPPH325;
Ephrin type-A receptor 6 (Q9UF33): 296CPPH299; Ephrin type-A
receptor 8 (P29322): 293CPPH296
The aligned amino acids are highlighted as bold. The half maximal inhibitory concentration (IC50) values of IL-7 in competition with the same phage clones are also shown
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at physiological pH and may be able to interact with
charged residues on the targeted protein.
The two peptides were co-localized with IL-7Rα
expressed by ADC-stimulated Jurkat cells (Fig. 1c-h) as
proven by the yellow/orange color obtained after over-
lapping the green staining of peptides (Fig. 1c and d)
with the red staining of IL-7Rα (Fig. 1e and f), attesting
for their specific interaction. Intensity of the IL-7Rα
staining using a monoclonal antibody was decreased by
57 % in the presence of P725, thereby suggesting that
this peptide competed with the antibody binding sites
on the receptor. Control samples were characterized by
very weak staining or no staining (data not shown),
which contributed to the validation of specific cell bind-
ing of the selected peptides.
In vitro characterization of the functionalized imaging
probe USPIO-P258
Peptide P258 was retained for the development of vec-
torized contrast agents. We confirmed by immunohis-
tochemistry that P258 stains synovial tissue from
patients with RA (Additional file 2: Figure S5); the weak
staining produced by control peptides P255 and P259
(data not shown) attested for the specific binding of P258
to IL-7R. After grafting to USPIO-258 (Additional file 2:
Figure S6A), the K*d of the vectorized contrast agent was
4.9 × 10−6 M for the binding to IL-7Rα (Additional file 2:
Figure S6B); with USPIO-P258 there was no binding to
the PFBB-coated ELISA plate, proving its specific inter-
action with the target. With the negative control contrast
agent, USPIO-PEG, there was negligible binding to IL-
7Rα at high concentrations. The IC50 of USPIO-P258
was of 6.6 × 10−6 M, suggesting that functionalized
nanoparticles may have the ability to dislocate IL-7
from IL-7Rα (Additional file 2: Figure S6C). The results
of the MTT assay demonstrated that USPIO-P258 did
not produce cytotoxic effects at either of the concentra-
tions or times of incubation tested in our experimental
conditions (Additional file 2: Figure S6D).
The binding of USPIO-P258 to ADC-stimulated Jurkat
cells was evaluated and compared to USPIO-PEG or to
NS Jurkat cells. The measurement of iron concentration
was significantly higher in ADC samples incubated with
USPIO-P258 as compared to NS samples or cells incu-
bated with USPIO-PEG (Fig. 2). At high iron concentra-
tions (i.e., 3 mM corresponding to 2.73 × 10−7 M
nanoparticles by assuming approximately 11,000 iron
atoms per particle [24]), USPIO-P258 was also captured
by NS cells (p < 0.01 vs. USPIO-PEG), but this may be
explained by the constitutive level of IL-7R expression.
Iron concentration measured on cell samples was then
converted into the number of USPIO-P258 particles
bound per cell. We have thereby obtained about 3 × 104
to 7.6 × 104 particles/ADC cell and about 7.3 × 103 to
4.2 × 104 particles/NS cell (Additional file 2: Figure
S6E). These estimations are in agreement with the data
published by other authors with regard to the number
of IL-7R molecules expressed by different types of T
cells [30].
The ability of USPIO-P258 to bind ADC-stimulated
cells was validated by MRI and the R2
Norm measurement,
but also by immunofluorescence that demonstrated co-
localization of USPIO-P258 (but not of USPIO-PEG)
with IL-7Rα expressed by ADC cells (Fig. 2; Additional
file 2: Figures S7A, B). There was significant correlation
between R2
Norm measured by MRI and RRFL measured
by immunofluorescence (Additional file 2: Figure S7C),
attesting for the specific binding of USPIO-P258; IL-7Rα
expression was about six times higher in ADC cells vs.
NS cells (Additional file 2: Figure S7D).
In vivo characterization of the functionalized imaging
probe USPIO-P258
USPIO-P258 has faster blood clearance as compared to
USPIO-PEG, as demonstrated by the Te1/2 (118 minutes
vs. 284 minutes for UPIO-PEG) and Cltot (0.595 ml/min/
kg vs. 0.116 ml/min/kg for USPIO-PEG). The VDss of
USPIO-P258 (0.1 L/kg) is about two times larger than
(See figure on previous page.)
Fig. 1 Apparent dissociation constant (Kd) values of the synthesized selected peptides and of IL-7 were determined for their binding to IL-7 receptor
(IL-7R) and fibronectin (FN) (a). The ratio between Kd values for FN over IL-7R binding are shown (b). The binding of peptides P725 (c) and
P258 (d) to Jurkat cells stimulated by 5-Aza-2′-deoxycytidine was compared to anti-IL-7R antibody (e and f), which co-localizes with peptides
as shown by their superposition (g and h). Peptide annotation: P722 C-PHPQRPA-C, P725 C-KIMKSMP-C, P726 C-ASACPPH-C, P258 ASACPPH
Table 2 Theoretical biochemical parameters of peptide P725
and P258 as estimated by using the ExPASy proteomics server,
proteomics and sequence analysis tools
Parameter Peptide P725 Peptide P258
Half-life 1.2 h 4.4 h
pI 8.90 6.78
LogP (of ionic species) −4.49 −7.66
LogP (of non-ionic species) −2.65 −0.31
LogD (at pH 7.4) −4.46 −4.58
GRAVY 0.344 −0.157
Aliphatic index 43.33 28.57
LogP and LogD were calculated by using the MarvinSketch 5.11.5 software
(2013, http://www.chemaxon.com). Calculator plugins were used for structure
property prediction and calculation. Half-life was theoretically estimated in
mammalian reticulocytes in vitro. Aliphatic index is the relative volume
occupied by aliphatic side chains. pI isoelectric point, LogP partition coefficient,
LogD distribution coefficient estimated at pH 7.4 and a salt concentration of
150 mM, GRAVY grand average of hydropathicity (predicts the hydrophobicity)
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that of USPIO-PEG (0.0475 L/kg), which is confined to
the vascular space (Table 3; Additional file 2: Figure
S7E). USPIO-P258 was found in urine at concentrations
six to eight times higher than USPIO-PEG (Additional
file 2: Figure S7F), the highest being observed at 120 -
minutes post injection.
The biodistribution of USPIO-P258 was evaluated by a
bi-exponential treatment of T2 relaxation curves, which
provided two relaxation components of the water pro-
tons, i.e., a fast component (R2–1) and a slow one (R2–2).
USPIO-P258 content in the kidney decreased over time,
concomitantly with the increase of urine concentration
(Additional file 2: Figures S7G-H). USPIO-PEG also
seems to be excreted, at least partly, via the renal system,
but its urinary excretion is delayed in comparison with
USPIO-P258. The other organs (liver, spleen, lungs) seem
only to be transited by USPIO-P258 via the circulatory sys-
tem, with no significant accumulation (Additional file 2:
Figures S8A-F), as opposed to USPIO-PEG, which seems to
accumulate in liver and lungs.
For the CIA experiments, only three out of eight
mice had signs of severe arthritis defined by a score of
4 according to the method of Brand et al. [27]. For the
MRI studies, CIA and healthy mice were injected with
either USPIO-P258 or USPIO-PEG and the limbs were
imaged by MRI at 7 T. Both RARE (raw images in
Additional file 2: Figure S9; color overlay in Fig. 3) and
FISP (Additional file 2: Figure S10) MRI sequences
demonstrated significant negative contrast in the hind
limbs of CIA mice, which was not equivalent to any of
the negative controls. The negative contrast was evi-
dent from the first 12 minutes post injection and per-
sisted until the end of the imaging session (about 2 h)
(Fig. 4a-b). The tissue contrasted by USPIO-P258 cor-
responds to the joints between the tarsal, metatarsal
and phalangeal bones and the associated soft tissue.
Considering the small size of these bones in mice, it
was not possible to distinguish their individual constit-
uents (synovium, cartilage, subchondral bone) by MRI;
they appeared as a continuous black trait on the nega-
tively contrasted images of the paw. In addition, the
susceptibility effect of iron oxide nanoparticles also
contributes to this continuous pattern of contrast.
Negative contrast was also observed at the knee.
The ΔSNR% measured on sagittal and coronal RARE
images (Fig. 4a-b) confirms the negative contrast pro-
duced by USPIO-P258 in hind limbs of CIA mice, where
it decreased to about −45 % by 12–25 minutes post in-
jection, and remained constant until 60–70 minutes
(around −40 %); at the end of the imaging session (about
2 h), ΔSNR% increased to around −30 %. USPIO-PEG
injected into CIA mice produced a decrease to −20 % to
−25 % of ΔSNR% 12–25 minutes post contrast, but the
negative contrast increased to −13 % to −11 % by the
end of the imaging session. The ΔSNR% values mea-
sured in healthy mice injected with USPIO-P258 or
USPIO-PEG were close to the pre-contrast level and
ranged between −5 % and −11 %. These results seem to
confirm the RA diagnostic potential of USPIO-P258,
probably via specific binding to IL-7Rα.
The biodistribution of contrast agents in the limbs
sampled from the mice at the end of the imaging session
was evaluated by relaxometry (Fig. 4c-d). The data dem-
onstrated an important accumulation of USPIO-P258 in
the limbs of mice with RA as compared to healthy mice
(p < 0.01). A significant difference (p < 0.05) was also ob-
served in comparison with CIA mice injected with
USPIO-PEG, confirming the specific targeting of IL-7Rα
by USPIO-P258. The results obtained in healthy mice
injected with contrast agents were not significantly dif-
ferent from those observed in the control mice not
receiving contrast agents.
The expression of IL-7Rα in the hind limbs of CIA
mice subjected to MRI studies was confirmed by immu-
nohistochemical analysis, whereas the Perls’-DAB stain-
ing was used to detect contrast agents in the limb
tissues (Fig. 5). The connective tissue and different cell
types in CIA or healthy tissues were observed using
Masson’s Trichrome staining. A prominent leucocyte in-
vasion was observed in the cartilage and synovial tissue
(See figure on previous page.)
Fig. 2 The binding of ultra-small superparamagnetic particles of iron oxide (USPIO)-P258 and of USPIO-poly(ethylene glycol) PEG (USPIO-PEG) to
Jurkat cells stimulated by 5-Aza-2′-deoxycytidine (ADC), or not stimulated (NS), is presented as Fe concentration (left histogram). The binding of
these contrast agents to ADC-stimulated Jurkat cells is also exemplified by the magnetic resonance image (right upper column); control represents
Jurkat cells not incubated with contrast agents and included in gelatin. USPIO-P258 and USPIO-PEG bound to ADC-stimulated Jurkat cells were
detected by immunofluorescence with anti-PEG antibody (green fluorescence) and co-localized with anti-IL-7 receptor (anti-IL-7R) antibody (red
fluorescence) on the same cells. *p < 0.05, **p < 0.01 for ADC vs. NS; §§p < 0.01 for USPIO-P258/ADC vs. USPIO-PEG/ADC; ##p < 0.01 for USPIO-P258/
NS vs. USPIO-PEG/NS
Table 3 Pharmacokinetic parameters of USPIO-P258 in comparison
to USPIO-PEG, as determined in healthy NMRI mice
Pharmacokinetic parameters USPIO-P258 USPIO-PEG
Te1/2 (minutes) 118 284
VDss (L/kg) 0.100 0.0475
Cltot (mL/min/kg) 0.595 0.116
USPIO ultra-small superparamagnetic particles of iron oxide, PEG poly(ethylene
glycol), Te1/2 elimination half-life, VDss volume of distribution steady state, Cltot
total clearance
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of CIA mice compared to healthy mice, which co-
localized with high IL-7Rα expression and iron staining
when USPIO-P258 was injected. IL-7Rα and USPIO de-
rivatives (USPIO-P258 or USPIO-PEG) were additionally
co-localized by immunofluorescence on the same paw
section (Fig. 6), USPIO being detected with an anti-
PEG antibody. PEG is used both as a stealth coating
material and as a linker between P258 and USPIO
(Additional file 2: Figure S6A). These results confirm
the very good co-localization of IL-7Rα with USPIO-
P258 but not with USPIO-PEG, thereby corroborating
the specific targeting.
The %DTA in post-contrast images of CIA mice
injected with USPIO-P258 and the TA occupied by IL-
7Rα staining on the paw sections of the same mice were
analyzed using ImageJ software and the results are pre-
sented in Fig. 7a. There was strong positive correlation
between the mean values of %DTA and those of TA for
IL-7Rα staining (r2 = 0.952), and between the severity
score of CIA and %DTA (r2 = 0.877) or TA for IL-7Rα
staining (r2 = 0.818) (Fig. 7b).
In vitro characterization of the blocking activity of P725
Jak/STAT is one of the main signaling pathways that are
activated by IL-7 upon binding to IL-7Rα [31]. Aiming
to validate the ability of P725 to prevent IL-7 binding to
its receptor and the triggering of Jak/STAT signaling
cascade, a competition experiment was performed by
treating ADC-stimulated Jurkat cells with IL-7 and
P725; anti-IL-7Rα antibody was used as a positive con-
trol. The phosphorylation of Tyr694 in STAT-5 was eval-
uated by immunofluorescence in treated cells. There was
an increase of 424 % increase in phospho-STAT-5 in
IL-7-treated cells as compared to ADC-treated con-
trols, which attested for its activation. Anti-IL-7Rα
antibody (p < 0.01) and P725 (p < 0.01) prevented IL-7
binding and STAT-5 activation, demonstrating a
pharmacological effect associated with its IL-7 compet-
ing activity (Additional file 2: Figures S11A and B).
IL-7R is internalized subsequent to IL-7 binding via
clathrin-dependent endocytosis, followed by its recycling
or degradation within lysosomes. We therefore repeated
the competition experiment with the aim of quantifying
the lysosome content of Jurkat cells and thus deduce the
outcome of IL-7R when its binding to IL-7 is prevented
by P725 (Additional file 2: Figure S12). The effects pro-
duced by anti-IL-7Rα antibody and P725 followed the
same pattern as that of phospho-STAT-5. IL-7 induced a
significant increase in lysosome content (398 % vs.
ADC-treated controls), suggesting endocytosis and lyso-
some degradation of IL-7R. The lysosome content of
Jurkat cells significantly diminished after treatment with
anti-IL-7Rα antibody (p < 0.05) or P725 (p < 0.05), sug-
gesting that both competitors prevent IL-7R endocytosis
followed by lysosome degradation induced by IL-7. This
phenomenon may explain the STAT-5 inactivation pro-
duced by both competitors.
Fig. 3 Color overlay of rapid acquisition with relaxation enhancement
(RARE) magnetic resonance images (spatial resolution = 156 × 90 μm)
of the hind limbs of mice with collagen-induced arthritis (CIA) (a) or
healthy mice (b) injected with either ultra-small superparamagnetic
particles of iron oxide (USPIO)-P258 or USPIO-poly(ethylene glycol)
(USPIO-PEG) in pre-contrast and about 2 h post contrast. Arrowheads
indicate the hind paw; arrow indicates the knee. Color overlays are
related to the negative signal enhancement, which is observed by the
shift of colors from blue to black; on the post-USPIO-P258 image of the
CIA mouse, arrowheads and arrow indicate the negatively contrasted
constituents of the hind limb. C calcaneus, CB coxal bones, K knee,
P paw, Ph phalanx, Mt metatarsal bones, T tibia
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Discussion
The clinical imaging methods currently used for RA
diagnosis and monitoring (i.e., radiography, computed
tomography, MRI and ultrasound) provide information
on bone erosions and joint space narrowing [20, 21];
however, no information is obtained on the cellular and
molecular mechanisms of the disease that precede the
development of destructive lesions, which sometimes
trigger serious debility in less than 2 years in 10 % of
cases. Most imaging probes used for RA diagnosis and
monitoring are unspecific, although several classic or
novel targeted imaging agents have been assessed, such
as 18F-fluorodeoxyglucose (18F-FDG), [11C]Choline, (R)-
[11C]PK11195 and other translocator protein (TSPO)-
targeted radiotracers, [67Ga]Citrate, [99mTc]- and [111In]
human immunoglobulin G (HIG), [99mTc]- and
[111In]anti-E-selectin, [99mTc]- and [111In]Octreotide,
[99mTc]Anti-TNF-α and [99mTc]Annexin V, etc. [21–23].
Among them, only 18F-FDG, TSPO-targeted radiotracers
(e.g., 11CPBR28, 18F-GE-180), the αvβ3-specific imaging
probe 68Ga-BNOTA-PRGD2 and the PET probe 18F-FHBG
employed for the imaging of reporter genes, are cur-
rently undergoing clinical trials according to the US
National Institutes of Health [32]. Examples of new
imaging tracers include 99mTc-labeled derivative of
octreotide peptide employed to image somatostatin re-
ceptor expressed by T lymphocytes [33], and several
radiotracers used to monitor therapy response in
human or experimental arthritis, such as 99mTc-NTP
15–5 targeted to proteoglycans in the RA joints [34],
111In-RGD2 (αvβ3-targeted),
111In-anti-fibroblast activa-
tion protein antibody and 111In-antimurine macrophage
antibody [35]. Therefore, there is active research to
meet the increasing demand of imaging methods and
probes able to provide precocious and reliable information
on the clinical outcome, pathophysiological process, the
disease severity and location, and the disease response to
novel molecular therapies.
The role of IL-7R and IL-7 in the pathogenesis of RA
is well-documented. Both molecules are expressed in RA
synovial tissue and blockade of the IL-7/IL-7R axis in
CIA results in significant clinical improvement. In
Fig. 4 Signal enhancement (% difference in signal-to-noise ratio (ΔSNR%)) measured on sagittal (a) and coronal (b) magnetic resonance images
of the paw in mice with collagen-induced arthritis (CIA) and healthy mice injected with ultra-small superparamagnetic particles of iron oxide
(USPIO)-P258 or USPIO-poly(ethylene glycol) (USPIO-PEG): n = 4 per experimental group; p < 0.01 for CIA mice injected with USPIO-P258 as
compared to all control groups, except for the coronal slices acquired at 26 minutes post contrast and compared to USPIO-PEG, for which
p < 0.05. For transverse relaxation rates (R2), R2(1) (c) and R2(2) (d) were measured on paws sampled from mice at the end of the imaging session
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Fig. 5 IL-7 receptor (IL-7Rα) expression detected by immunohistochemical analysis is compared to ultra-small superparamagnetic particles of iron
oxide (USPIO)-P258 and USPIO-poly(ethylene glycol) (USPIO-PEG) (stained by Perls’-3,3'-diaminobenzidine (DAB)) capture in the hind limbs of mice
with collagen-induced arthritis studied by magnetic resonance imaging. Histological structures were examined using Masson’s Trichrome staining.
For each experimental group, the different staining methods were applied on sequential sections from the same mouse joints
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addition, IL-7Rα was recently identified as a diagnostic
marker in early RA, and a marker of severity and poor
response to therapy in early and established disease. Our
attempts to develop in vivo IL-7Rα imaging tracers are
based on these observations, and fit in a novel approach
to the taxonomy of inflammatory joint disorders, in
which diagnostic and therapeutic decisions are based on
the identification of specific molecular pathways, rather
than broad clinical diagnostic categories. Thus, we iden-
tified several IL-7Rα-specific heptapeptides, which are
potential vectors for RA-dedicated imaging probes.
Some of them are putative therapeutic agents that work
by blocking IL-7 ligation to IL-7R. To the best of our
knowledge, no other IL-7Rα-targeted small molecule has
been discovered and exploited in the framework of RA
diagnosis and treatment.
During the screening of the randomized cyclic hepta-
peptide phage display library, it was observed that most
clones had high affinity against FN type III-like domain
of IL-7Rα (A131-I231), suggesting its involvement in lig-
and binding. Indeed, specialized literature has shown
that 5 of the 12 amino acids (S51, F99, L100, L101, I102,
K104, D122, H154, K157, Y159, V160, H211) are involved in
IL-7 ligation [36]. As a consequence, excessive preselec-
tion against FN has led to a decline in phage pool affin-
ity for IL-7Rα during the third and particularly the
fourth round of panning. The peptide sequence of the
12 phage clones selected from the second and the third
rounds of panning presented a high frequency of basic
(His, Lys) and alcohol (Ser) amino acids, but also a Pro
repetition. The first three amino acids are potentially in-
volved in IL-7Rα binding based on the proposed model
[36], whereas Pro can induce 20° distortions in the axis
of an alpha helix, which suggests that peptides can
present a certain 3D conformation. The three best
peptide clones (C-PHPQRPA-C, C-KIMKSMP-C and
C-ASACPPH-C) characterized by the highest specific
affinity against IL-7Rα have shown interesting hom-
ologies with molecules involved in signal transduction, cell
adhesion, extracellular matrix, cytoskeletal organization, cell
migration, embryogenesis and inflammation, proving that
their selection was not accidental.
Before synthesis, peptide C-PHPQRPA-C presented
the highest binding specificity, whereas peptide C-
ASACPPH-C was the weakest candidate. However, after
synthesis, peptide C-PHPQRPA-C (encoded as P722)
Fig. 6 Immunofluorescent co-localization of ultra-small superparamagnetic particles of iron oxide (USPIO)-P258 (stained red by Texas Red) with
IL-7 receptor alpha (IL-7Rα) (stained green by fluorescein) on the joints of mice with collagen-induced arthritis is evidenced by the yellow/orange color
obtained after merging the microphotographs (Merge). No co-localization was observed for USPIO-PEG. Note that anti-PEG antibody recognizes both
USPIO-P258 and USPIO-PEG via their PEG coat
Burtea et al. Arthritis Research & Therapy  (2016) 18:230 Page 15 of 19
had lost its affinity against IL-7Rα, displaying equivalent
binding to FN. Peptide C-KIMKSMP-C (encoded as
P725) had better affinity for FN than for IL-7Rα, but its
μM Kd indicated stronger binding than that of P722. To
our surprise, the highest specific binding to IL-7Rα was
observed in the case of peptide C-ASACPPH-C
(encoded as P726), which thus became the most promis-
ing candidate for diagnostic applications. Aiming to
eventually improve its affinity constant, the peptide was
synthesized in a linear version (encoded as P258),
Fig. 7 Analysis by ImageJ of the total area (TA) occupied by black pixels on post-contrast magnetic resonance (MR) images and by the brown
staining of IL-7Rα on immunohistochemical microphotographs. a Percentage difference of TA (%DTA) on post-contrast MR images as compared
to the pre-contrast images and the TA of IL-7 receptor alpha (IL-7Rα) staining for each of the four mice in the collagen-induced arthritis (CIA)
group injected with ultra-small superparamagnetic particles of iron oxide (USPIO)-P258. b Correlation between %DTA of post-contrast MR images
in the CIA group injected with USPIO-P258, the TA of IL-7R staining and the CIA score
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checking in this way the necessity of Cys-constraint.
This chemical strategy has indeed enhanced its affinity
in the order of nanomolar and improved its specificity
against IL-7Rα. The linear peptides present a more flex-
ible spatial conformation, with functional groups opti-
mally exposed for a chemical interaction with the
targeted biomarker [37].
One can conclude that peptide P258 presents a
chemical interaction with IL-7Rα, the conformational
compatibility (imposed by Cys-constraint) not being a
prerequisite. Peptide P258 was thus subsequently used
to functionalize a MRI contrast agent such as USPIO
(USPIO-P258). This reversal of the affinity parameters
of the three candidate peptides after their synthesis is
explained by the monovalent exposure to the target,
after being presented in a pentavalent display on the
phage entity. It is very well-known that pentavalent
presentation is responsible for an avidity effect that
may facilitate the binding of certain peptides to their
target.
In our experimental conditions, IL-7 was characterized
by a Kd (1.7 × 10
−7 M) close to that of P258, being infer-
ior to the value reported previously (i.e., 2 × 10−10 M
against the high-affinity IL-7R and 10−8 M against the
low-affinity IL-7R) [38]. The truncated recombinant IL-
7Rα protein (241 amino acids instead of 459 amino
acids), removed from its cellular environment, may be
responsible for the lower affinity constant observed in
our experimental conditions. In addition, two antibodies
were used to detect IL-7, which means that additional
rinsing steps may contribute to extensive protein removal
and lower apparent affinity. However, an interesting obser-
vation was that P725 displayed competitive abilities against
IL-7, which highlighted its role as a potential therapeutic
agent by blocking IL-7 binding to its receptor.
With regard to imaging applications of our IL-7Rα-
targeted peptide, USPIO-P258 had good ability to distin-
guish stimulated from non-stimulated Jurkat cells and
its binding to IL-7Rα co-localized with anti-IL-7Rα anti-
body, confirming its specificity. The blood clearance of
USPIO-P258 is much faster than that of USPIO-PEG,
and its elimination is likely to mainly occur via a renal
pathway. In addition, USPIO-P258 does not seem to ac-
cumulate in the main organs, which are simply transited
via the blood stream. We have previously observed [24,
25] that peptide grafting to USPIO is responsible for en-
hanced blood clearance, an enlarged VDss and increased
urinary excretion, probably due to diminished PEG graft-
ing that is partly replaced by peptides on the surface of
nanoparticles. Moreover, these biodistribution and phar-
macokinetic properties are amplified by peptides with a
hydrophilic character.
USPIO-P258 produced a significant negative contrast
in the paws of CIA mice, which was not equivalent to
any of the control mice. The negative contrast corre-
sponded to the tarsal, metatarsal and phalangeal joints,
and persisted for about 2 hours post injection. The
contrast agent accumulation in the hind limbs of CIA
mice was confirmed by relaxometry and histochemical
analysis at the end of the imaging session. The contrast
observed at long image acquisition times suggests the
specific binding to the targeted receptor, as most of the
contrast agent has been cleared from the blood. On
histological examination, USPIO-P258 co-localized
with IL-7Rα expression in the paws of CIA mice,
attesting for its specific accumulation at this level. A
non-specific accumulation of USPIO-PEG was also ob-
served in the diseased paws, probably as a result of its
phagocytosis by the local macrophages, but its capture
was less important as compared to USPIO-P258. Taken
together, these results confirm the imaging ability of
USPIO-P258 as an IL-7Rα imaging marker, the diag-
nostic faculty being furthermore confirmed by the high
positive correlation between its accumulation in the
diseased paws, the IL-7Rα expression and the disease
severity.
One of the most important signaling pathways that
are activated by IL-7 ligation to its receptor is Jak/
STAT, which triggers the phosphorylation of cytoplas-
mic tyrosine kinases associated with IL-7Rα and the
common γ-chain, respectively. Once activated, Jak1 can
phosphorylate the Tyr449 residue of IL-7Rα, which re-
cruits the transcription factor STAT5 (a heterodimer
comprising STAT5a and STAT5b) that is itself tyrosine-
phosphorylated by Jak. Phosphorylated STAT5 can
dimerize and translocate to the nucleus, where it regu-
lates the transcription of several genes involved in T
cell survival and proliferation [2–4]. The inhibition of
IL-7 engagement with its receptor by a specific com-
petitor may have potential therapeutic effects in various
inflammatory conditions such as RA. The competitive
character of P725 was thus confirmed by immunofluor-
escence, using ADC-stimulated Jurkat cells as a model.
P725 inhibited IL-7-induced STAT5 activation by 82 %,
which was similar to that produced by anti-IL-7Rα anti-
body (86 %).
It has been shown that IL-7Rα is rapidly inactivated
by lysosome and proteasome-dependent degradation
subsequent to its endocytosis triggered by IL-7 activa-
tion. In fact, IL-7 signal transduction requires
clathrin-dependent endocytosis of IL-7Rα followed by
its degradation by proteolysis [30]. In order to check
whether STAT5 inactivation induced by P725 treatment is
associated with a diminished IL-7Rα endocytosis, we have
indirectly measured the lysosome content of Jurkat cells
in the same experimental conditions as for STAT5. Our
results confirm the increased lysosome content of Jurkat
cells stimulated by IL-7, and suggest that P725 ligation to
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IL-7Rα blocks IL-7 binding and inhibits the endocytosis
and lysosome-dependent degradation of IL-7Rα.
Conclusions
In the present work, we designed IL-7Rα-targeted pep-
tides. The design of cytokine agonists and antagonists of
small molecular size is of notable pharmaceutical inter-
est in RA [35] and our work integrates with this general
optic. The two IL-7Rα-targeted heptapeptides are hydro-
philic and ionized at physiological pH, the blocking one
being cyclic (P725), whereas the imaging peptide is
linear (P258). The potential blocking effect of P725
was validated in vitro, by preventing STAT5 activation
induced by IL-7. Considering its equivalent affinity for
IL-7Rα and FN, P725 is not a suitable candidate for
molecular imaging applications due to the high potential
background generated by the ubiquitously expressed FN.
P258 grafted to USPIO produced strong negative contrast
in experimental arthritis, even at two hours post-injection
when the blood concentration of the imaging probe was
very low (18 % from C0). The co-localization of USPIO-
P258 with IL-7Rα-expressing cells in CIA synovitis dem-
onstrates its specific binding to the targeted receptor. In
CIA conditions, USPIO-P258 is able to discriminate the
level of IL-7R expression and the disease severity.
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